Soligenix (STU:DOA) 3-Year EPS without NRI Growth Rate : 56.90% (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Soligenix 3-Year EPS without NRI Growth Rate?

Soligenix's EPS without NRI for the three months ended in Mar. 2024 was €0.00.

During the past 3 years, the average EPS without NRI Growth Rate was 56.90% per year. During the past 5 years, the average EPS without NRI Growth Rate was 34.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 31.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Soligenix was 56.90% per year. The lowest was -42.10% per year. And the median was 24.10% per year.

Competitive Comparison of Soligenix's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Soligenix's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Soligenix's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Soligenix's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Soligenix's 3-Year EPS without NRI Growth Rate falls into.

Soligenix 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Soligenix (STU:DOA) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Soligenix 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Soligenix's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Soligenix (STU:DOA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soligenix Inc (STU:DOA) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

SNGX:USA

Address

29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540

Website

https://www.soligenix.com

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Soligenix (STU:DOA) Headlines

No Headlines